- Home
- CWEN vs CELC Comparison
CWEN vs CELC Comparison
Compare CWEN & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWEN | CELC |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.1B |
| IPO Year | 2013 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CWEN | CELC |
|---|---|---|
| Price | $35.92 | $110.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $39.25 | ★ $100.13 |
| AVG Volume (30 Days) | ★ 1.2M | 629.3K |
| Earning Date | 02-23-2026 | 11-12-2025 |
| Dividend Yield | ★ 4.93% | N/A |
| EPS Growth | ★ 125.75 | N/A |
| EPS | ★ 2.34 | N/A |
| Revenue | ★ $1,375,000,000.00 | N/A |
| Revenue This Year | $3.94 | N/A |
| Revenue Next Year | $14.18 | N/A |
| P/E Ratio | $15.24 | ★ N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $24.50 | $7.58 |
| 52 Week High | $36.89 | $116.44 |
Technical Indicators
Market Signals| Indicator | CWEN | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 62.42 | 60.08 |
| Support Level | $31.81 | $103.00 |
| Resistance Level | $36.50 | $112.69 |
| Average True Range (ATR) | 1.16 | 6.44 |
| MACD | 0.37 | 0.07 |
| Stochastic Oscillator | 87.21 | 70.07 |
Price Performance
Historical ComparisonAbout CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into Flexible Generation, renewables and Corporate divisions.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.